MedTrace Logo

An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo

NCT01439815 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-04-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after up to 14 days of at home dosing.

Conditions

  • Allergic Rhinitis
  • Allergic Conjunctivitis

Interventions

DRUG

Fluticasone Propionate Nasal Spray

two sprays in each nostril once daily

DRUG

Saline Nasal Spray

two sprays in each nostril once daily

Sponsors & Collaborators

  • ORA, Inc.

    lead INDUSTRY

Principal Investigators

  • Tarek Shazly, MD · ORA, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01439815 on ClinicalTrials.gov